Abstract:Abstract The success of immune checkpoint inhibitors in the treatment of various types of cancers and their continued growth in the market have driven burgeoning interests in developing more drugs in this category. However, the intrinsic complexity of the immunological models and the variable drug responses among different cancer types have become the most prominent challenges. To facilitate large scale research projects and drug discovery of immune checkpoint inhibitors, we conducted a comprehensive protein profiling of ATCC’s vast portfolio of human tumor and immune cell lines for several established and novel immune checkpoint molecules. Based on this protein profiling data, we generated immune checkpoint reporter cancer cell lines with high expression of endogenous immune checkpoint molecule ligands (PD-L1, CD155, and B7-H3). The reporter system contains a gamma interferon activation site (GAS)-response element upstream of the luciferase gene, preventing luciferase expression when the immune checkpoint molecule ligand binds to its corresponding receptor that suppresses T cell-mediated antitumor activity. In the presence of a relevant immune checkpoint inhibitor, a luciferase expression-based bioluminescent signal is produced, which can be readily detected and quantitated to evaluate the efficacy, potency, and dynamics of the inhibitor. Our data showed that the bioluminescence in the reporter cancer cells increased approximately 100-250 folds in a dose-dependent manner in response to interferon gamma stimulation, which mimics the signaling from activated CD8+ cytotoxic T cells. The bioluminescence increased approximately 50-100 folds in response to CD8+ primary T cell-conditioned media stimulation. In particular, we observed up to 5-fold increase in luciferase signal from our PD-L1 reporter cell line in response to co-culture with CD8+ primary T cells in the presence of an anti-PD-L1 blocking antibody in a dose-dependent manner. The luciferase expression and endogenous immune checkpoint molecule ligand expression were well maintained after the cell lines had reached >30 population doubling level. These results highlight the robustness and responsiveness of the reporter system for the assessment of T cell-mediated immune responses triggered by checkpoint inhibitors. These immune checkpoint reporter cancer cell lines yield exceptional in vitro and ex vivo assay sensitivity and reproducibility, while simplify the complex immunological model by providing physiologically relevant expression of immune checkpoint molecule ligands, in comparison to similar assays with an artificial checkpoint ligand overexpression system. Citation Format: Hyeyoun Chang, Kevin Tyo, John Foulke, Luping Chen, Zhizhan Gu, Fang Tian. Immune checkpoint reporter cell lines based on the protein profiling of ATCC cell lines for cancer immunotherapy drug screening. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6643.

A Reporter Gene Assay for Determining the Biological Activity of Therapeutic Antibodies Targeting TIGIT

Development of a reporter gene method to measure the bioactivity of anti-CD38 × CD3 bispecific antibody

Generation and Characterization of Polyclonal Antibodies Against Mouse T-cell Immunoglobulin and Immunoreceptor Tyrosine-Based Inhibitory Domain by DNA-based Immunization.

A Novel Human Anti-Tigit Monoclonal Antibody with Excellent Function in Eliciting NK Cell-Mediated Antitumor Immunity.

Development of a mechanism of action-reflective, dual target cell-based reporter bioassay for a bispecific monoclonal antibody targeting human CTLA-4 and PD-1

Abstract 6643: Immune checkpoint reporter cell lines based on the protein profiling of ATCC cell lines for cancer immunotherapy drug screening

A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function

Abstract 3256: TIGIT Humanized BALB/c Mouse: A Novel Animal Model for Preclinical Studies of Human TIGIT Antibodies

Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies

Multiplex T Cell Stimulation Assay Utilizing a T Cell Activation Reporter-Based Detection System

Development of bioassay platforms for biopharmaceuticals using Jurkat-CAR cells by AICD

Potent Apoptosis Induction by a Novel Trispecific B7-H3xCD16xTIGIT 2+1 Common Light Chain Natural Killer Cell Engager

GAS-Luc2 Reporter Cell Lines for Immune Checkpoint Drug Screening in Solid Tumors

Rapid, Sensitive and Cost-Effective Determination of Immune Checkpoint Inhibitor Activity Using a Magnetic Bead-Based Binding Assay.

TIGIT, A Novel Therapeutic Target for Tumor Immunotherapy

TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer

Abstract 88: Novel cell-based bioassays enable preclinical animal studies during immuno-oncology drug development

Abstract 3274: Novel cell-based bioassays for mono- and multi-specific antibodies targeting PD-1/PD-L1 for combination immunotherapy

Novel Reporter System Monitoring IL-18 Specific Signaling Can Be Applied to High-Throughput Screening

Antigen-Dependent Inducible T-Cell Reporter System for PET Imaging of Breast Cancer and Glioblastoma

Abstract 1875: Novel cell-based bioassays for monoclonal antibody and bispecific molecules in PD-1 blockade monotherapy and combination therapy